untreated, EBV-positive diffuse large B-cell lymphoma
Showing 1 - 25 of >10,000
EBV-Positive DLBCL, Nos Trial in Guangzhou, Shanghai (Selinexor, R-CHOP Protocol)
Recruiting
- EBV-Positive Diffuse Large B-Cell Lymphoma, Nos
- Selinexor
- R-CHOP Protocol
-
Guangzhou, Guangdong, China
- +1 more
Nov 10, 2022
Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma Grade IIIb Trial in Guangzhou (Toripalimab,
Recruiting
- Diffuse Large B Cell Lymphoma
- +5 more
- Toripalimab, Rituximab
- R-CHOP Protocol
-
Guangzhou, Guangdong, ChinaDepartment of hematology department, Nanfang hospital
Apr 6, 2022
Aggressive Non-Hodgkin Lymphoma, ALK-Positive Large B-Cell Lymphoma, B-Cell Lymphoma, Unclassifiable, With Features Intermediate
Recruiting
- Aggressive Non-Hodgkin Lymphoma
- +8 more
- Polatuzumab Vedotin
- +6 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jan 26, 2023
DLBCL Trial (Acalabrutinib, Rituximab)
Not yet recruiting
- Diffuse Large B-Cell Lymphoma
- Acalabrutinib
- Rituximab
- (no location specified)
Jul 11, 2023
Recurrent DLBCL, Refractory Diffuse Large B-cell Lymphoma Trial in Tianjin (RC19D2 cell injection)
Recruiting
- Recurrent Diffuse Large B-Cell Lymphoma
- Refractory Diffuse Large B-cell Lymphoma
- RC19D2 cell injection
-
Tianjin, Tianjin, ChinaHematology Hospital of the Chinese Academy of Medical Sciences
Sep 14, 2023
High-Dose Methotrexate Clearance in Diffuse Large B-Cell
Recruiting
- Central Nervous System Lymphoma
- Diffuse Large B-Cell Lymphoma
- Non-Interventional Study
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Sep 8, 2023
Large B-cell Lymphoma, Diffuse Large B Cell Lymphoma Trial in Homburg (R-miniCHOP + Acalabrutinib, R-miniCHOP)
Not yet recruiting
- Large B-cell Lymphoma
- Diffuse Large B Cell Lymphoma
- R-miniCHOP + Acalabrutinib
- R-miniCHOP
-
Homburg, Saarland, GermanySaarland University Medical Center
Apr 19, 2023
Diffuse Large B-cell Lymphoma Recurrent, Diffuse Large B Cell Lymphoma Refractory Trial in Hangzhou (Anlotinib HCl, Rituximab,
Recruiting
- Diffuse Large B-cell Lymphoma Recurrent
- Diffuse Large B Cell Lymphoma Refractory
- Anlotinib hydrochloride, Rituximab, gemcitabine, oxaliplatin
-
Hangzhou, Zhejiang, ChinaZhejiang Cancer Hospital
Oct 12, 2023
Diffuse Large B Cell Lymphoma | DLBCL Recurrent/Refractory Trial (ZR2-ICE)
Not yet recruiting
- Diffuse Large B Cell Lymphoma | Diffuse Large B-Cell Lymphoma Recurrent/Refractory
- (no location specified)
Sep 5, 2023
Diffuse Large B-cell Lymphoma (DLBCL) Trial in Westbury (Odronextamab, Rituximab, Cyclophosphamide)
Recruiting
- Diffuse Large B-cell Lymphoma (DLBCL)
- Odronextamab
- +5 more
-
Westbury, New YorkClinical Research Alliance Inc
Oct 13, 2023
Relapsed or Refractory Diffuse Large B-cell Lymphoma Trial in Beijing (BEBT-908 for injection)
Active, not recruiting
- Relapsed or Refractory Diffuse Large B-cell Lymphoma
- BEBT-908 for injection
-
Beijing, ChinaCancer Hospital Chinese Academy of Medical Sciences
Oct 8, 2023
DLBCL Trial (Polatuzumab Vedotin)
Not yet recruiting
- Diffuse Large B-Cell Lymphoma
- Polatuzumab Vedotin
- (no location specified)
Jul 12, 2023
Recurrent ALK Positive Large B-Cell Lymphoma, Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between
Not yet recruiting
- Recurrent ALK Positive Large B-Cell Lymphoma
- +28 more
- Biospecimen Collection
- +5 more
-
Rochester, MinnesotaMayo Clinic in Rochester
Aug 17, 2022
Diffuse Large B Cell Lymphoma Trial in Shanghai (Zanubrutinib, Polatuzumab vedotin and Rituximab)
Recruiting
- Diffuse Large B Cell Lymphoma
- Zanubrutinib, Polatuzumab vedotin and Rituximab
-
Shanghai, Shanghai, ChinaZhongshan Hospital,Fudan University
Jul 10, 2023
DLBCL Trial in Jinan (Mitoxantrone Hydrochloride Liposome Injection)
Not yet recruiting
- Diffuse Large B-Cell Lymphoma
- Mitoxantrone Hydrochloride Liposome Injection
-
Jinan, Shandong, ChinaAffiliated Cancer Hospital of Shandong First Medical University
May 16, 2023
Diffuse Large B Cell Lymphoma Trial in Shanghai (Zanubrutinib, Polatuzumab Vedotin, Rituximab)
Recruiting
- Diffuse Large B Cell Lymphoma
- Zanubrutinib, Polatuzumab Vedotin, Rituximab
-
Shanghai, Shanghai, ChinaZhongshan Hospital,Fudan University
Jul 10, 2023
Diffuse Large B-cell Lymphoma Trial (Rituximab, Mitoxantrone HCl liposome, Cyclophosphamide)
Not yet recruiting
- Diffuse Large B-cell Lymphoma
- Rituximab
- +4 more
- (no location specified)
Mar 9, 2023
DLBCL - Diffuse Large B Cell Lymphoma, Follicular Lymphoma Trial in Xiamen (Lenalidomide combined with G-CHOP (LO CHOP))
Recruiting
- DLBCL - Diffuse Large B Cell Lymphoma
- Follicular Lymphoma
- Lenalidomide combined with G-CHOP (LO CHOP)
-
Xiamen, Fujian, ChinaBing Xu
Nov 28, 2023
Diffuse Large B Cell Lymphoma (DLBCL) Trial in Toronto (glofitamab)
Not yet recruiting
- Diffuse Large B Cell Lymphoma (DLBCL)
-
Toronto, Ontario, CanadaPrincess Margaret Cancer Centre
Sep 18, 2023
Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma
Not yet recruiting
- Lymphoma, B-Cell
- +6 more
- Plasma metabolomic profile by Ultra-high performance liquid chromatography with quadrupole time-of-flight mass spectrometry (UPLC-QTOFMS)
-
Guayaquil, Guayas, EcuadorInstituto Oncológico Nacional Dr. Juan Tanca Marengo
Apr 27, 2023
Diffuse Large B Cell Lymphoma Trial in Rouen (Measure of the circulating tumor DNA)
Not yet recruiting
- Diffuse Large B Cell Lymphoma
- Measure of the circulating tumor DNA
-
Rouen, FranceCentre Henri Becquerel
Nov 17, 2023
Diffuse Large B-cell Lymphoma Trial in Changchun (Mitoxantrone HCl liposome injection, RiTUXimab Injection, Cyclophosphamid)
Not yet recruiting
- Diffuse Large B-cell Lymphoma
- Mitoxantrone hydrochloride liposome injection
- +4 more
-
Changchun, Jilin, ChinaThe First Bethune Hospital of Jilin University
Aug 15, 2023
DLBCL, High-grade B-cell Lymphoma Trial (Loncastuximab Tesirine)
Not yet recruiting
- Diffuse Large B-Cell Lymphoma
- High-grade B-cell Lymphoma
- Loncastuximab Tesirine
- (no location specified)
Dec 13, 2022
Diffuse Large B-cell Lymphoma Trial (Rituximab, Mitoxantrone HCl liposome, Isophosphamide)
Not yet recruiting
- Diffuse Large B-cell Lymphoma
- Rituximab
- +7 more
- (no location specified)
Mar 23, 2023